Molecular Oncology

Research interest

Our group is interested in studying how cellular signaling (vg. MAPK, AKT) can affect the process of cellular transformation. To this end, we have developed several lines of research including chemical and genetic approaches applied to in vitro models of cancer cell lines and in vivo mouse models. For example, in the case of MAPK we have been able to uncover the implication of erk1/2 in the process of viral oncogenesis. We are currently focusing on the study of the role of MAPK-dependent signaling in human sarcoma, a poorly studied pathology but with high incidence in childhood. By using an experimental mouse model based on chemical carcinogenesis we expect to clarify MAPK´s role in the development of soft tissue sarcomas.

Our study encompasses conventional chemotherapy as well as novel compounds used in targeted therapy, such as Imatinib, Palbociclib or Sorafenib, among others. The main goal is to understand how cellular signaling can affect the response to cancer therapy and its involvement in the development of resistant phenotypes. On this subject, our group has great expertise in the study of how p38 MAPK or ERK1/2 modulate the cellular responses to several antitumor agents including Cisplatin, 5-FU, Sorafenib or Imatinib.

Role of cellular signaling in the response to radiotherapy

In the case of ionizing radiation, we are focused on elucidating the role of cellular signaling in the development of cancer cell radioresistance. Also, our group has great interest in the role of cellular signaling in the radiosensitizer potential of several chemotherapeutics agents such as 5-FU or Palbociclib. In addition, our laboratory is also studying the interplay between key proteins in DNA damage response (vg. ATM, p53) and cellular signaling.

Finally, our group also maintains a line of research on the molecular mechanisms by which nuclear steroid hormone receptors regulate gene expression, focusing on the characterization of new transcriptional co-regulators of nuclear receptors and studying their possible involvement in the initiation and development of tumors in tissues directly regulated by endocrine signals, such as the mammary gland or prostate.

  • 100% 100%


    • Título: Autofagia en cáncer: implicación de MAPKS en resistencia y supresión tumoral
      Entidad financiadora: Ministerio de Economía y Competitividad
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/01/2013   hasta: 31/12/2015
    • Título: Papel de la señalización intracelular mediada por proteínas quinasas en los fenómenos de quimio y radio resistencia
      Entidad financiadora: Fundación Leticia Castillejo
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/01/2014   hasta: 29/09/2015
    • Título: Papel de la señalización intracelular mediada por proteínas quinasas en los fenómenos de quimio y radio resistencia
      Entidad financiadora: Fundación Leticia Castillejo
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 04/07/2012   hasta: 04/09/2013
    • Título: Bases moleculares de la transformación y supresión tumoral asociada a la expresión del gen E1A de adenovirus: desarrollo de modelos in vivo
      Entidad financiadora: Consejería de Educación y Ciencia, JCCM
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/04/2010   hasta: 31/03/2013
    • Título: Papel de la ruta de señalización P38MAPK en terapia de cáncer basada en daño genotóxico
      Entidad financiadora: Ministerio de Ciencia e Innovación
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/11/2009   hasta: 31/10/2012
    • Título: Papel de la señalización intracelular mediada por proteínas quinasas en los fenómenos de quimio y radio resistencia
      Entidad financiadora: Fundación Leticia Castillejo
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/06/2011   hasta: 30/09/201
  • 100% 100%


  • Romero-Macías JR, Pascual-Serra R, Roche O, Ruiz-Marcos F, Serrano-Martínez A, González-Aguado P, Belandia B, Ruiz-Hidalgo MJ, Sánchez-Prieto R. Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells. Clin Transl Oncol. 2019. 21[9]: 1280-1285. doi: 10.1007/s12094-019-02041-x. (A).   
  • Fernández-Aroca DM, Roche O, Sabater S, Pascual-Serra R, Ortega-Muelas M, Sánchez Pérez I, Belandia B, Ruiz-Hidalgo MJ, Sánchez-Prieto R. P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy. Cancer Lett. 2019. 451: 23-33. doi: 10.1016/j.canlet.2019.02.049. (A).   

  • Meléndez-Rodríguez F, Urrutia AA, Lorendeau D, Rinaldi G, Roche O, Böğürcü-Seidel N, Ortega Muelas M, Mesa-Ciller C, Turiel G, Bouthelier A, Hernansanz-Agustín P, Elorza A, Escasany E, Li QOY, Torres-Capelli M, Tello D, Fuertes E, Fraga E, Martínez-Ruiz A, Pérez B, Giménez-Bachs JM, Salinas-Sánchez AS, Acker T, Sánchez Prieto R, Fendt SM, De Bock K, Aragonés J. HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis. Cell Rep. 2019. 26[9]: 2257-2265.e4. doi: 10.1016/j.celrep.2019.01.106. (A).   

  • Serrano-Oviedo L, Ortega-Muelas M, García-Cano J, Valero ML, Cimas FJ, Pascual-Serra R, Fernandez-Aroca DM, Roche O, Ruiz-Hidalgo MJ, Belandia B, Giménez-Bachs JM, Salinas AS, Sanchez-Prieto R. Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. PLoS One. 2018. 13[7]: e0200878. doi: 10.1371/journal.pone.0200878. (A).   

  • Meléndez-Rodríguez F, Roche O, Sanchez-Prieto R, Aragones J. Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. Front Oncol. 2018. 8: 214. doi: 10.3389/fonc.2018.00214. (A).   

  • Salinas-Sánchez AS, Serrano-Oviedo L, Nam-Cha SY, Roche-Losada O, Sánchez-Prieto R, Giménez-Bachs JM. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study. Clin Genitourin Cancer. 2017. 15[6]: e923-e933. doi: 10.1016/j.clgc.2017.05.016. (A).   

  • Cimas FJ, Callejas-Valera JL, García-Olmo DC, Hernández-Losa J, Melgar-Rojas P, Ruiz-Hidalgo MJ, Pascual-Serra R, Ortega-Muelas M, Roche O, Marcos P, Garcia-Gil E, Fernandez-Aroca DM, Ramón Y Cajal S, Gutkind JS, Sanchez-Prieto R. E1a is an exogenous in vivo tumour suppressor. Cancer Lett. 2017. 399: 74-81. doi: 10.1016/j.canlet.2017.04.010. (A).   

  • Labrousse-Arias D, Martínez-Alonso E, Corral-Escariz M, Bienes-Martínez R, Berridy J, Serrano-Oviedo L, Conde E, García-Bermejo ML, Giménez-Bachs JM, Salinas-Sánchez AS, Sánchez-Prieto R, Yao M, Lasa M, Calzada MJ. VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1. J Cell Biol. 2017. 216[3]: 835-847. doi: 10.1083/jcb.201608024. (A).  

  • Serrano-Oviedo L, Giménez-Bachs JM, Nam-Cha SY, Cimas FJ, García-Cano J, Sánchez-Prieto R, Salinas-Sánchez AS. Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis. Urol Oncol. 2017. 35[3]: 114.e15-114.e22. doi: 10.1016/j.urolonc.2016.10.010. [Epub 2016](A).   

  • Cheray M, Bessette B, Lacroix A, Mélin C, Jawhari S, Pinet S, Deluche E, Clavère P, Durand K, Sanchez-Prieto R, Jauberteau MO, Battu S, Lalloué F. KLRC3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness. J Cell Mol Med. 2017. 21[2]: 244-253. doi: 10.1111/jcmm.12960. [Epub 2016]. (A).    

  • García-Cano J, Roche O, Cimas FJ, Pascual-Serra R, Ortega-Muelas M, Fernández-Aroca DM, Sánchez-Prieto R. p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story. Front Cell Dev Biol. 2016. 4: 69. doi: 10.3389/fcell.2016.00069. (A).   

  • De la Cruz-Morcillo MA, Berger J, Sánchez-Prieto R, Saada S, Naves T, Guillaudeau A, Perraud A, Sindou P, Lacroix A, Descazeaud A, Lalloué F, Jauberteau MO. p75 neurotrophin receptor and pro-BDNF promote cell survival and migration in clear cell renal cell carcinoma. Oncotarget. 2016. 7[23]: 34480-34497. doi: 10.18632/oncotarget.8911. (A).  

  • Valero ML, Sabariegos R, Cimas FJ, Perales C, Domingo E, Sánchez-Prieto R, Mas A. Hepatitis C Virus RNA-Dependent RNA Polymerase Interacts with the Akt/PKB Kinase and Induces Its Subcellular Relocalization. Antimicrob Agents Chemother. 2016. 60[6]: 3540-3550. doi: 10.1128/AAC.03019-15. (A).  
  • Sabater S, Pastor-Juan Mdel R, Berenguer R, Andres I, Sevillano M, Lozano-Setien E, Jimenez-Jimenez E, Rovirosa A, Sanchez-Prieto R, Arenas M. Analysing the integration of MR images acquired in a non-radiotherapy treatment position into the radiotherapy workflow using deformable and rigid registration. Radiother Oncol. 2016. 119[1]: 179-184. doi: 10.1016/j.radonc.2016.02.032. [Epub 2016]. (A).  
  • Bargiela-Iparraguirre J, Prado-Marchal L, Fernandez-Fuente M, Gutierrez-González A, Moreno-Rubio J, Muñoz-Fernandez M, Sereno M, Sanchez-Prieto R, Perona R, Sanchez-Perez I. CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. Sci Rep. 2016. 6: 21519. doi: 10.1038/srep21519. (A).  
  • Cimas FJ, Callejas-Valera JC, Sanchez-Prieto R. MKP1: Jekyll and Hyde for E1A. Aging (Albany NY). 2016. 8[2]: 214-215. (A).  
  • Klionsky DJ, ..., Sanchez-Prieto R, …, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016. 12[1]: 1-222. doi: 10.1080/15548627.2015.1100356.  (A).  
  • Sabater S, Andres I, Jimenez-Jimenez E, Berenguer R, Sevillano M, Lopez-Honrubia V, Rovirosa A, Sanchez-Prieto R, Arenas M. Rectal contrast increases rectal dose during vaginal cuff brachytherapy. Brachytherapy. 2016. 15[1]: 35-39. doi: 10.1016/j.brachy.2015.10.005. [Epub 2015]. (A).  
  • Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS, Sánchez-Prieto R. MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells. Oncotarget. 2015. 6[42]: 44095-44107. doi: 10.18632/oncotarget.6574. (A).  
  • González MJ, Ruiz-García A, Monsalve EM, Sánchez-Prieto R, Laborda J, Díaz-Guerra MJ, Ruiz-Hidalgo MJ. DLK1 is a novel inflammatory inhibitor which interferes with NOTCH1 signaling in TLR-activated murine macrophages. Eur J Immunol. 2015. 45[9]: 2615-2627. doi: 10.1002/eji.201545514. [Epub 2015]. (A). 
  • García-Cano J, Ambroise G, Pascual-Serra R, Carrión MC, Serrano-Oviedo L, Ortega-Muelas M, Cimas FJ, Sabater S, Ruiz-Hidalgo MJ, Sanchez Perez I, Mas A, Jalón FA, Vazquez A, Sánchez-Prieto R. Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. Oncotarget. 2015. 6[17]: 15551-15565. (A).
  • Valero ML, Cimas FJ, Arias L, Melgar-Rojas P, García E, Callejas-Valera JL, Cano JG, Serrano Oviedo L, de la Cruz-Morcillo MA, Sánchez-Pérez I, Sánchez-Prieto R. E1a promotes c-Myc-dependent replicative stress: Implications in glioblastoma radiosensitization. Cell Cycle. 2014. 13[1]: 52-61. doi: 10.4161/cc.26754. [Epub 2013]. (A).
  • de la Cruz-Morcillo MA, García-Cano J, Arias-González L, García-Gil E, Artacho-Cordón F, Ríos-Arrabal S, Valero ML, Cimas FJ, Serrano-Oviedo L, Villas MV, Romero-Fernández J, Núñez MI, Sánchez-Prieto R. Abrogation of the p38 MAPK ? signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. Cancer Lett. 2013; pii: S0304-3835(13)00096-7. doi: 10.1016/j.canlet.2013.01.050. (A).
  • Elorza A, Soro-Arnáiz I, Meléndez F, Rodríguez V, Marsboom G, de Cárcer G, Acosta B, Albacete L, Ordóñez A, Serrano-Oviedo L, Giménez JM, Vara A, Salinas A, Sánchez-Prieto R, Martín R, Sánchez F, Malumbres M, Landázuri MO, Aragonés J. HIF2? Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5. Mol Cell. 2012. pii: S1097-2765(12)00817-9. (A).
  • Klionsky DJ, …, Sanchez-Prieto R, …, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012. 8[4]: 445-544. (A).
  • Giménez-Bachs JM, Salinas-Sánchez AS, Serrano-Oviedo L, Nam-Cha SH, Rubio-Del Campo A, Sánchez-Prieto R. Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis. Scand J Urol Nephrol. 2012; 46[5]: 358-364. (A).
  • Hossain S, de la Cruz-Morcillo MA, Sanchez-Prieto R, Almazan G. Mitogen-activated protein kinase p38 regulates krox-20 to direct schwann cell differentiation and peripheral myelination. Glia. 2012. 60[7]: 1130-1144. (A).
  • de la Cruz-Morcillo MA, Sánchez-Prieto R. Autop38-phagy and apop38-tosis in genotoxic stress: A strange duo.Autophagy. 2012. 8[1]: 135-7. [Epub 2011]. (A).
  • de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-González L, Melgar-Rojas P, Galán-Moya EM, García-Gil E, García-Cano J, Sánchez-Prieto R. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene. 2012. 31[9]: 1073-1085. [Epub 2011]. (A).
  • Salinas-Sánchez AS, Giménez-Bachs JM, Serrano-Oviedo L, Nam Cha S, Sánchez-Prieto R. Role of Mitogen-Activated Protein Kinase (MAPK) in the Sporadic Renal Cell Carcinoma. Actas Urol Esp. 2012. 36[2]: 99-103. [Epub 2011]. (A).
  • Galan-Moya EM, de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Melgar-Rojas P, Losa JH, Salcedo M, Fernández-Aramburo A, Cajal SR, Sánchez-Prieto R. Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLC. PLoS One. 2011. 6[12]: e28406. (A).
  • Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R. ERK2, but not ERK1, mediates acquired and ‘de novo’ resistance to imatinib mesylate: implication for CML therapy. PLoS One. 2009. 4[7]: 604-607. (A).
  • Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramirez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Cajal SR, Silvio Gutkind J, Sanchez-Prieto R. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Int J Cancer. 2008. 122[2]: 289-297. (A).
  • Callejas-Valera JL, Guinea-Viniegra J, Ramírez-Castillejo C, Recio JA, Galan-Moya EM, Martinez N, Rojas JM, Ramón Y Cajal S, Sánchez-Prieto R. E1A gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKPS up-regulation: Implication in V-H-ras induced senescence. J Biol Chem. 2008. 283[9]: 13450-13458. (A).
  • Romero J, Zapata I, Córdoba S, Jimeno JM, López-Martín JA, Tercero JC, De La Torre A, Vargas JA, Molerón R, Sánchez-Prieto R. In vitro radiosensitisation by trabectedin in human cancer cell lines. Eur J Cancer. 2008. 44[12]: 1726-1733. (A).
  • Pascual A, Pariente M, Godinez JM, Sanchez-Prieto R, Atienzar M, Segura M, Poblet E.. High prevalence of human papillomavirus 16 in penile carcinoma. Histol Histopathol. 2007. 22[2]: 177-183. (A).
  • Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon y Cajal S. Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006. 28[1]: 143-148. (A).
  • Guinea J, Martínez N, Aceves CI, Galán E, de la Cruz MA, Callejas JL, Arraiga A, Ramírez C, Villas MV, Rojas JM, Sánchez-Prieto R. PKB/Akt media la radio sensibilidad asociada a Ataxia Telangiectasia. Oncología. 2005. 28: 329-337. (A).
  • Poblet E, Jimenez F, de Cabo C, Prieto-Martin A, Sanchez-Prieto R. The calcium-binding protein calretinin is a marker of the companion cell layer of the human hair follicle. Br J Dermatol. 2005. 152[6]: 1316-1320. (A).
  • Viniegra JG, Martinez N, Modirassari P, Losa JH, Parada CC, Lobo VJ, Luquero CI, Alvarez-Vallina L, Cajal S, Rojas JM, Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005. 280[6]: 4029-4036. [Epub 2004]. (A).
  • Sanchez-Arevalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Tipping AJ, Viniegra JG, Hernandez Losa J, Parada Cobo C, Galan Moya EM, Gayoso Cruz J, Melo JV, Ramon y Cajal S, Sanchez-Prieto R. Modulation of the p38 MAPK pathway through Bcr/Abl: Implications in the cellular response to Ara-C. Biochem J. 2005. 387[1]: 231-238. (A).  

Maria Jose Ruiz Hidalgo (Ext. 2919/2981)



Permanent staff

PhD students
Postdoctoral Researcher
Collaborating clinicians
  • José Ramón Moreno Macías (Ext. 96149)
  • Sebastiá Sabater
  • Syong Nam Cha

  • Antonio Fernández Aramburo 

Phone: (+34) 967 599 200

Contact information

Facultad de Medicina de Albacete Universidad de Castilla-La Mancha C/ Almansa, 14. 02008 Albacete (España)
telefono (-34) 967 599 200, Ext. 2987 fax (+34) 967 599 327
  • 100% 100%